Protein-tyrosine phosphatase 1B as a potential drug target for obesity

Shrikrishna Dadke1, Jonathan Chernoff

  • 1Fox Chase Cancer Center, W 451, 333 Cottman Avenue, Philadelphia, PA 19111-2497, USA.

Current Drug Targets. Immune, Endocrine and Metabolic Disorders
|December 20, 2003
PubMed

Insights

Obesity is a growing global epidemic. Targeting protein tyrosine-phosphatase 1B (PTP1B) may offer a new therapeutic strategy by improving leptin and insulin signaling.

Area of Science:

  • Biochemistry
  • Metabolic Disorders
  • Pharmacology

Background:

  • Obesity is a major global health concern, recognized as a top epidemic by the WHO.
  • Leptin and insulin resistance are key factors contributing to the development of obesity.
  • Protein tyrosine-phosphatase 1B (PTP1B) negatively regulates both leptin and insulin signaling pathways.

Purpose of the Study:

  • To review the role of PTP1B in leptin and insulin signaling.
  • To evaluate PTP1B as a potential therapeutic target for obesity treatment.

Main Methods:

  • Literature review of studies investigating PTP1B function.
  • Analysis of evidence linking PTP1B to leptin and insulin resistance.
  • Discussion of PTP1B as a drug target.

Main Results:

  • PTP1B acts as a crucial negative regulator of leptin and insulin signaling.
  • Inhibition of PTP1B demonstrates potential for improving metabolic signaling.

Conclusions:

  • PTP1B is a significant therapeutic target for combating obesity.
  • Further research into PTP1B inhibitors could lead to effective obesity treatments.

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...